Indications for: ALREX
Seasonal allergic conjunctivitis.
In two double-masked, placebo-controlled six-week environmental studies of 268 patients with seasonal allergic conjunctivitis, Alrex, when dosed 4 times per day was superior to placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. Alrex reduced bulbar conjunctival injection and itching, beginning approximately 2 hours after instillation of the first dose and throughout the first 14 days of treatment.
1 drop into affected eye(s) 4 times daily.
Ocular fungal, viral, or mycobacterial infections.
Reevaluate if no improvement after 2 days. Prescribe initially and renew after 14 days only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Soft contact lenses (remove, may reinsert 10 minutes after instillation). Pregnancy (Cat.C). Nursing mothers.
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation.